Fundz

Immuno Met Therapeutics reported raising $842,000 in an initial SEC Form D filing, from an offering of $10 Million

PRIVATEFeb 05, 2026$842.2K of $10M raised

Amount Raised

$842,000

$842,000 sold, per SEC Form D (first sale Jan 21, 2026)

Round Type

Venture

HoustonBiotechnologyHealth CareTherapeutics

Quick answer

ImmunoMet Therapeutics raised $842,000 in a funding round, dated January 21, 2026. ImmunoMet Therapeutics is based in Houston, Texas, United States.

How much did ImmunoMet Therapeutics raise?
ImmunoMet Therapeutics raised $842,000 in a funding round on January 21, 2026.
What does ImmunoMet Therapeutics do?
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies.
Where is ImmunoMet Therapeutics based and how big is it?
ImmunoMet Therapeutics is based in Houston, Texas, United States. Fundz records about 7 employees.
Who are the decision-makers at ImmunoMet Therapeutics?
Fundz holds 1 contact at ImmunoMet Therapeutics, including the Board Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as ImmunoMet Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Prolium Bioscience raised $50M (Series A) on March 5, 2026.
  • NexCure raised $19M (Series A) on March 5, 2026.
  • Os Therapies raised $2M on March 4, 2026.
  • Antiverse raised $9.3M (Series A) on March 3, 2026.
  • Polares Medical SA raised $50M (Series C) on March 3, 2026.
  • KALA BIO, Inc. raised $1.8M on March 3, 2026.

Who to call at ImmunoMet Therapeutics, and when

A new round usually means ImmunoMet Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ImmunoMet Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ImmunoMet Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ImmunoMet Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ImmunoMet Therapeutics

Location

Houston, Texas, United States

About

ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and select cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good tolerability. In fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plan to progress into Phase 2 PoC study in IPF patients in 4Q2021. The company was founded in 2015, is a spin-off from HanAll Biopharma, a Korean midsized public company, and has raised $31 MM post-spin-off.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ImmunoMet Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsBenjamin C., Board DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for ImmunoMet Therapeutics's next move

See what Strategic adds

ImmunoMet Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.